Trials / Completed
CompletedNCT00789698
Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia
A Phase 3 Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Lurasidone in Subjects With Schizophrenia (PEARL 3 Extension Study)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 240 (actual)
- Sponsor
- Sumitomo Pharma America, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR long term among schizophrenic outpatients with chronic schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lurasidone HC1 | Lurasidone 40-160 mg/day flexibly dosed. |
| DRUG | Quetiapine XR | Quetiapine XR 200-800 mg/day flexibly dosed. |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2008-11-13
- Last updated
- 2015-06-12
- Results posted
- 2012-08-21
Locations
65 sites across 6 countries: United States, Colombia, India, Romania, Russia, Ukraine
Source: ClinicalTrials.gov record NCT00789698. Inclusion in this directory is not an endorsement.